ALMS · Alumis Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74M | - | $2.07M | $2.67M | $17.39M | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $81.54M | - | $97.84M | $108.75M | $41.96M | - | $87.82M | $48.56M |
| SG&A | $18.61M | - | $19.52M | $34.45M | $5.63M | - | $10.57M | $7.58M |
| Total Operating Expenses | $100.15M | - | $117.36M | $143.21M | $47.59M | - | $98.40M | $56.14M |
| D&A | $871.0K | - | $900.0K | $900.0K | $758.0K | - | $300.0K | $800.0K |
| Operating Income | ($98.41M) | - | ($115.29M) | ($140.54M) | ($47.59M) | - | ($43.76M) | ($56.14M) |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | $0 | ($8.56M) | - | - | - | - |
| Net Income | ($93.05M) | - | ($110.75M) | $59.32M | ($98.96M) | - | ($43.38M) | ($36.29M) |
| EPS - Basic | ($0.74) | - | ($1.06) | $0.78 | ($21.03) | - | ($1.73) | ($17.13) |
| EPS - Diluted | ($0.74) | - | ($1.06) | $0.77 | ($21.03) | - | ($19.76) | ($17.13) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.88M | $89.67M | $65.26M | $151.75M | $112.07M | $169.53M | $53.94M | $46.00M |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $11.59M | $10.11M | $4.55M | $14.98M | $7.47M | $9.62M | $6.44M | $1.12M |
| Current Assets | $532.41M | $318.23M | $393.29M | $517.56M | $225.53M | $306.19M | $377.35M | $224.86M |
| Total Assets | $671.59M | $411.94M | $488.01M | $610.92M | $261.30M | $340.99M | $412.56M | $89.61M |
| Current Liabilities | $70.90M | $73.32M | $65.42M | $85.58M | $60.45M | $50.91M | $33.52M | $33.41M |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $104.57M | $110.64M | $103.24M | $125.60M | $92.98M | $80.89M | $64.17M | $64.70M |
| Stockholders' Equity | $567.02M | $301.30M | $384.77M | $485.33M | $168.31M | $260.10M | $348.39M | ($262.35M) |
| Retained Earnings | ($994.93M) | ($901.88M) | ($808.95M) | ($698.19M) | ($757.51M) | ($658.55M) | ($563.79M) | ($470.68M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($87.08M) | - | - | - | ($44.26M) | - | - | - |
| Investing Cash Flow | ($285.69M) | - | - | - | ($18.81M) | - | - | - |
| Financing Cash Flow | $346.99M | - | - | - | $129.15M | - | - | - |
| CapEx | $164.0K | - | - | - | $155.0K | - | - | - |
| Free Cash Flow | ($87.25M) | - | - | - | ($44.42M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | -5652.4% | - | -5580.4% | -5271.5% | -273.7% | - | - | - |
| EBITDA margin | -5602.4% | - | -5536.9% | -5237.8% | -269.3% | - | - | - |
| Net margin | -5344.8% | - | -5360.7% | 2225.1% | -569.1% | - | - | - |
| Free cash flow margin | -5011.3% | - | - | - | -255.4% | - | - | - |
| FCF / Net income | 0.94 | - | - | - | 0.45 | - | - | - |
| R&D / Revenue | 4683.5% | - | 4735.5% | 4079.3% | 241.3% | - | - | - |
| SG&A / Revenue | 1068.9% | - | 944.9% | 1292.2% | 32.4% | - | - | - |
| Effective tax rate | - | - | - | -16.9% | - | - | - | - |
| Return on assets | -13.9% | - | -22.7% | 9.7% | -37.9% | - | -10.5% | -40.5% |
| Return on equity | -16.4% | - | -28.8% | 12.2% | -58.8% | - | -12.5% | 13.8% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 7.51 | 4.34 | 6.01 | 6.05 | 3.73 | 6.01 | 11.26 | 6.73 |
| Quick ratio | 7.51 | 4.34 | 6.01 | 6.05 | 3.73 | 6.01 | 11.26 | 6.73 |
| Cash ratio | 0.90 | 1.22 | 1.00 | 1.77 | 1.85 | 3.33 | 1.61 | 1.38 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.18 | 1.37 | 1.27 | 1.26 | 1.55 | 1.31 | 1.18 | -0.34 |
| Liabilities / Assets | 0.16 | 0.27 | 0.21 | 0.21 | 0.36 | 0.24 | 0.16 | 0.72 |
| Efficiency | ||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.07 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | 3.9x | - | - | - | - |
| P / B | 4.9x | - | 1.1x | 0.5x | 0.1x | - | 1.6x | - |
| P / S | 1582.3x | - | 201.1x | 86.2x | 0.8x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | -90.0% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -106.8% | - | -163.5% | -150.3% | - | - | - | - |
| Net income growth (YoY) | 6.0% | - | -155.3% | - | - | - | - | - |
| EPS growth (YoY) | 96.5% | - | 94.6% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -96.4% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 236.9% | 15.8% | 10.4% | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$24.05M totalSingle Reportable Segment$24.05M · 100.0%
Product / service
$24.05M totalLicense$17.39M · 72.3%
Collaboration Revenue$6.66M · 27.7%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ALUMIS INC. against the 5 most active filers in the same SIC group.